Corporate Use Sample Clauses
Corporate Use. Xxxxxxxx shall identify itself in all relevant transactions as a licensee of, and separate legal entity from, NGS as opposed to an integrated, divisional or consolidated part of NGS’ business. Xxxxxxxx shall not use any of the Licensed Property in Xxxxxxxx’x name or in the name of any operating entity or business formed by Xxxxxxxx or in which Xxxxxxxx has a business or financial interest, without the prior written consent of NGS. Xxxxxxxx shall not use or incorporate any of the Licensed Property on or in connection with any business to business communications (boat leases, employment agreements, food services, etc.), business cards, stationery items (except Xxxxxxxx to consumer material, specifically excluding Xxxxxxxx Travel Insurance brochure and any correspondence solely related to Xxxxxxxx Travel Insurance), or other similar materials. Xxxxxxxx further agrees that it shall not use or incorporate, in any manner or form, any of the Licensed Property as a domain name, nor shall Xxxxxxxx seek trademark, copyright or domain name registration of the same, without the prior written consent of NGS.
Corporate Use. Any indebtedness of the Borrower or any Guarantor or any of their Restricted Subsidiaries is declared to be or otherwise becomes due and payable prior to its specified maturity as a result of an event of default (however described).
Corporate Use. Licensee shall not use the Trademarks in Licensee's name or in the name of any operating entity formed by Licensee, without the prior consent of Wilsxx.
Corporate Use. If you are using the Service on behalf of a company, you further represent and warrant that you are authorized to act and enter into contracts on behalf of that company.
Corporate Use. Notwithstanding the above provisions, in no event shall the following constitute Financial Indebtedness:
Corporate Use. If any of the foregoing provisions becomes inconsistent with provisions adopted under the aegis of EMMI (or any successor to that function of EMMI as determined by the Bank) in respect of EURIBOR, the Bank may by notice to the Borrower amend the provision to bring it into line with such other provisions. If the Screen Rate becomes permanently unavailable, the EURIBOR replacement rate will be the rate (inclusive of any spreads or adjustments) formally recommended by (i) the working group on euro risk-free rates established by the European Central Bank (ECB), the Financial Services and Markets Authority (FSMA), the European Securities and Markets Authority (ESMA) and the European Commission, or (ii) the European Money Market Institute, as the administrator of EURIBOR, or (iii) the competent authority responsible under Regulation (EU) 2016/1011 for supervising the European Money Market Institute, as the administrator of the EURIBOR, or (iv) the national competent authorities designated under Regulation (EU) 2016/1011, or (v) the European Central Bank. If the Screen Rate becomes permanently unavailable and no EURIBOR replacement rate is formally recommended as provided above, EURIBOR shall be the rate (expressed as a percentage rate per annum) which is determined by the Bank to be the all-inclusive cost to the Bank for the funding of the relevant Tranche based upon the then applicable internally generated Bank reference rate or an alternative rate determination method reasonably determined by the Bank. To: European Investment Bank From: Scinai Immunotherapeutics Ltd. Date: Subject: Finance Contract between European Investment Bank and BiondVax Pharmaceuticals Ltd. dated 19 June 2017, as amended and restated on 20 June 2019, and as further amended on 11 January 2022, 9 August 2022 and 24 November 2023 and on [______] 2024 (the “Finance Contract”) FI number 88205 Serapis number 2015-0572 Dear Sirs, We refer to the Finance Contract. This is a Compliance Certificate. Terms defined in the Finance Contract have the same meaning when used in this Compliance Certificate. We hereby confirm:
Corporate Use promptly after a Responsible Officer of the Borrower obtains knowledge thereof, the details of any judgment or order of a court, arbitral body or agency which is made against the Borrower or any Restricted Subsidiary and which might have a Material Adverse Effect, provided that any notice given to the Bank pursuant to this Clause 13.3 shall be accompanied by a statement of a Responsible Officer of the Borrower setting forth material details of the occurrence referred to therein and stating what action the relevant Borrower has taken and proposes to take with respect thereto, if any. Notwithstanding the foregoing, the obligations in this Clause 13.3 may be satisfied by furnishing the Borrower’s or Holdings’ (or any direct or indirect parent thereof), as applicable, Forms 20-F, 10-K, 10-Q, 8-K or 6-K, as applicable, filed with the SEC.
Corporate Use. Sublicensee shall not use the Trademarks in Sublicensee's name or in the name of any operating entity formed by Sublicensee without the prior consent of Sublicensor and Wilsxx.
Corporate Use. Any corporate action, legal proceedings or other procedure or step is taken in relation to the suspension of payments, a moratorium of any indebtedness, dissolution, administration or reorganisation (by way of voluntary arrangement, composition or otherwise), including bankruptcy, controlled management, suspension of payments, arrangement with creditors and judicial liquidation proceedings or any analogous procedure or step is taken under any applicable law in any jurisdiction or an order is made or an effective resolution is passed for the winding-up of the Borrower or any of the Restricted Subsidiaries (other than any Immaterial Subsidiary) or any Guarantor, or if the Borrower or any Restricted Subsidiaries (other than any Immaterial Subsidiary) or any Guarantor takes steps towards a substantial reduction in its capital, is declared insolvent or ceases or resolves to cease to carry on the whole or any substantial part of its business or activities, or any situation similar to any of the above occurs under any applicable law.
Corporate Use. Security on assets or property of the Borrower or any Restricted Subsidiary securing Financial Indebtedness or other obligations of the Borrower or such Restricted Subsidiary owing to the Borrower or another Restricted Subsidiary, or Security in favour of the Borrower or any Restricted Subsidiary;